Primate liver as an alternative substrate in EmA testing: implications for celiac disease serology

Background Endomysial antibody (EmA) testing by immunofluorescence assay (IFA) on primate esophagus is widely used as reference approach in celiac disease (CD) serology in the United States (US). Practical constraints related to tissue availability and variability have motivated the evaluation of alternative substrates. Methods We compared analytical performance between the following substrates: primate esophagus (reference), primate liver, and a tTG-transfected cell-based assay (CBA) using 54 celiac disease-positive sera (EmA-positive, anti-tTG IgA-positive, and/or anti-dGP-IgG-positive) and 62 non-celiac disease controls (autoimmune liver disease, symptomatic controls, healthy) at screening dilution (1:10) and serial dilution up to 1:100,000. Agreement analyses included negative percent agreement (NPA), positivity in CD-positive samples, 95% Wilson confidence intervals, and discrepant result characterization. Results At screening dilution, NPA was 100% (62/62) for esophagus and 98.4% (61/62) for both liver and tTG-transfected cells. Among CD-positive samples at 1:10, positivity was 74.1% (40/54) on esophagus, 96.3% (52/54) on liver, and 100% (54/54) on tTG-transfected cells. Of the 14 esophagus-negative CD-positive samples, liver classified 12/14 as positive and the tTG -CBA classified 14/14 as positive. Titer-dependent positivity declined in parallel across substrates (1:100: 59.3–68.5%; 1:1000: 18.5–24.1%), with overlapping confidence intervals. Discrepant cases (esophagus-negative but liver-positive) were consistently positive on tTG-CBA. Conclusion Primate liver demonstrates higher screening-dilution positivity than primate esophagus, supporting its use as a scalable alternative substrate in EmA-IFA. The tTG-transfected CBA showed the highest positivity and may serve as a complementary confirmatory platform. Primate esophagus retained complete negative agreement in this cohort, whereas primate liver and the tTG-transfected CBA each showed one reactive control sample. Larger multicenter studies with histology-linked outcomes are warranted.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-16
DOI
https://doi.org/10.3389/fimmu.2026.1939825
Primary Topic
Celiac Disease Research and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Primate liver as an alternative substrate in EmA testing: implications for celiac disease serology

Michael Schwalbe, Danielle A. Cervasio, Rama Chaar, Marco Kai et al.
1 links
Frontiers in Immunology
Celiac Disease Research and Management
article

Primate liver as an alternative substrate in EmA testing: implications for celiac disease serology

Michael Schwalbe, Danielle A. Cervasio, Rama Chaar, Marco Kai, Tanja Seifert, Maite Sabalza
article en

Abstract

Background Endomysial antibody (EmA) testing by immunofluorescence assay (IFA) on primate esophagus is widely used as reference approach in celiac disease (CD) serology in the United States (US). Practical constraints related to tissue availability and variability have motivated the evaluation of alternative substrates. Methods We compared analytical performance between the following substrates: primate esophagus (reference), primate liver, and a tTG-transfected cell-based assay (CBA) using 54 celiac disease-positive sera (EmA-positive, anti-tTG IgA-positive, and/or anti-dGP-IgG-positive) and 62 non-celiac disease controls (autoimmune liver disease, symptomatic controls, healthy) at screening dilution (1:10) and serial dilution up to 1:100,000. Agreement analyses included negative percent agreement (NPA), positivity in CD-positive samples, 95% Wilson confidence intervals, and discrepant result characterization. Results At screening dilution, NPA was 100% (62/62) for esophagus and 98.4% (61/62) for both liver and tTG-transfected cells. Among CD-positive samples at 1:10, positivity was 74.1% (40/54) on esophagus, 96.3% (52/54) on liver, and 100% (54/54) on tTG-transfected cells. Of the 14 esophagus-negative CD-positive samples, liver classified 12/14 as positive and the tTG -CBA classified 14/14 as positive. Titer-dependent positivity declined in parallel across substrates (1:100: 59.3–68.5%; 1:1000: 18.5–24.1%), with overlapping confidence intervals. Discrepant cases (esophagus-negative but liver-positive) were consistently positive on tTG-CBA. Conclusion Primate liver demonstrates higher screening-dilution positivity than primate esophagus, supporting its use as a scalable alternative substrate in EmA-IFA. The tTG-transfected CBA showed the highest positivity and may serve as a complementary confirmatory platform. Primate esophagus retained complete negative agreement in this cohort, whereas primate liver and the tTG-transfected CBA each showed one reactive control sample. Larger multicenter studies with histology-linked outcomes are warranted.

Frontiers in ImmunologyVol. 17
Prometheus Biosciences (United States) (US), Euroimmun Medizinische Labordiagnostika (Germany) (DE)
Good health and well-being
Celiac Disease Research and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon